Adding Palbociclib to Standard Care Improved PFS in Triple-Positive Breast Cancer

MedPage Today) — Findings from the phase III PATINA trial, presented at the San Antonio Breast Cancer Symposium, showed that adding the CDK4/6 inhibitor palbociclib (Ibrance) to current standard-of-care therapy following induction chemotherapy…